Merck's Bio-Based HPLC Solvents Target GMP Labs Seeking Greener Workflows
Merck's bio-based HPLC solvents claim a 25.9% CO2e reduction with no method revalidation required -- a key consideration for regulated QC labs.
Breaking News
Apr 28, 2026
Pharma Now Editorial Team

Merck Group has introduced a bio-based solvent portfolio for high-performance liquid chromatography (HPLC), positioning the offering as a drop-in replacement for conventional acetonitrile, methanol and ethanol. For QA directors and analytical lab managers operating under 21 CFR Part 211 or ICH Q10 frameworks, the central question is whether the switch can be made without triggering method revalidation -- and Merck's claim that it can carries significant procurement and compliance implications.
The portfolio, marketed under the LiChrosolv line, is produced from renewable feedstocks and is engineered for compatibility with existing HPLC and LC-MS systems. Merck states the solvents achieve an average reduction of 25.9% in CO2e compared to fossil-fuel-derived chromatography solvents, while maintaining analytical performance standards. The company describes the products as designed to integrate into existing methods without requiring redevelopment -- a critical consideration in regulated environments where analytical consistency underpins batch release and stability testing.
Karen Madden, Chief Technology Officer of Merck's Life Science business, stated: "Our new bio-based HPLC solvents represent the next generation of high-performance liquid chromatography. Customers are looking for solutions that help reduce environmental impact without compromising performance quality." The portfolio is positioned to support applications across drug development, manufacturing quality control, environmental analysis and diagnostics.
For procurement and QA teams evaluating a transition, the absence of required method revalidation -- if substantiated through internal comparability studies -- could meaningfully reduce the cost and timeline of adoption. However, regulated sites will need to assess supplier qualification requirements, review certificate of analysis specifications against current validated method parameters, and confirm extractables and leachables profiles are consistent with existing solvent grades before any site-level change control is initiated.
